2015
DOI: 10.3109/10428194.2015.1016928
|View full text |Cite
|
Sign up to set email alerts
|

Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the18F-fluorodeoxyglucose-positron emission tomography era

Abstract: Bone marrow biopsy is recommended for staging of classical Hodgkin lymphoma. The aim of this study was to compare bone marrow evaluation by histology with that obtained by (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET). One hundred and three cases of Classical Hodgkin Lymphoma were reviewed. All patients were submitted to FDG-PET evaluation. Bone marrow biopsy results were compared with clinical data and FDG-PET results. Ninety-one cases had available bone marrow biopsies. Overall, there were … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 21 publications
0
2
0
Order By: Relevance
“…in spite of the advances like positron emission tomography, BM biopsy is still essential to confirm BM involvement in Hl (11). although BM involvement has been reported to be less common in Hl when compared to non-Hodgkin lymphomas (4), it is still essential to do BM staging in Hl as it has prognostic significance (5).…”
Section: Discussionmentioning
confidence: 99%
“…in spite of the advances like positron emission tomography, BM biopsy is still essential to confirm BM involvement in Hl (11). although BM involvement has been reported to be less common in Hl when compared to non-Hodgkin lymphomas (4), it is still essential to do BM staging in Hl as it has prognostic significance (5).…”
Section: Discussionmentioning
confidence: 99%
“…BM studies are usually done as a part of the staging workup for HL because its involvement is considered as stage IV disease with poorer prognosis and reduced survival. 1,5,6,8 When compared with non-Hodgkin lymphomas, HL involving marrow is relatively rare with an incidence of 3 to 18%. 1,[9][10][11] HL invariably arises in the lymph nodes, and primary extranodal HL is very rare.…”
Section: Discussionmentioning
confidence: 99%